Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
AQST Catalyst Timeline
Dated clinical, regulatory and corporate events for Aquestive Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aquestive Therapeutics, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How AQST actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | Anaphylm (dibutepinephrine) Sublingual Film (AQST-109) | NDA Submission | NDA |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DESF Small MoleculesCompletedNCT07703982 | Allergic Reaction | Phase 2 | COMPLETED | 68 | May 21, 2025 | ||||||
| Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or with individual dose determined according to age and weight category Small MoleculesMarketedNCT03428360 | Epilepsy | Approved | COMPLETED | 149 | Jun 25, 2020 | ||||||
| Ondansetron Small MoleculesNot countedNCT01217190 | Nausea and Vomiting, Postoperative | Phase 1/2 | COMPLETED | 48 | Oct 6, 2008 | ||||||
| Diazepam Buccal Film Small MoleculesMarketedNCT03953820 | Epilepsy | Approved | COMPLETED | 90 | Jul 31, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every AQST program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Anaphylm™ (epinephrine) Sublingual Film | severe allergic reactions, including anaphylaxis | 2025-06-25 | Elicits Rapid and Consistent Pharmacokinetic and Pharmacodynamic ResponsesRead More | Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy SummitRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Davis Matthew W.Officer (Chief Development Officer) | Sell | -7,197 87,500 held | $3.55 | 11/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AQST
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 0.3 % | 34.38 M | 7.43 M |
Ownership Trends
AQST Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How AQST ranks across every disease it competes in
AQST News
Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference
Aquestive Therapeutics announced its participation in the Jefferies Global Healthcare Conference from November 16-19. The management team will present on November 16 at 10:00 am GMT and will conduct one-on-one investor meetings. A webcast of the presentation will be available for 30 days following the event.
Read more →Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting
Aquestive Therapeutics will present multiple studies at the 2026 ACAAI Annual Meeting. Key presentations include pharmacokinetic evaluations of Anaphylm™ (dibutepinephrine) sublingual film. The product aims to provide a novel oral treatment for severe allergic reactions. The meeting will take place from November 12-16, 2026, in Phoenix, Arizona.
Read more →Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Aquestive Therapeutics reported its third quarter 2026 financial results, highlighting the acceptance of the Anaphylm NDA resubmission with a PDUFA goal date of March 16, 2027. The company is preparing for a potential U.S. launch of Anaphylm, the first oral medication for severe allergic reactions. Additionally, AQST-108 is advancing in clinical trials for atopic dermatitis.
Read more →Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET
Aquestive Therapeutics will report its third quarter 2026 financial results on November 3, 2026. A conference call for investors is scheduled for November 4, 2026, at 8:00 a.m. ET. The company is known for its innovative delivery technologies and is advancing treatments for allergic reactions and dermatological conditions.
Read more →Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
Aquestive Therapeutics announced that the FDA has accepted its resubmission of the New Drug Application for Anaphylm, a sublingual film intended for treating Type I allergic reactions. The FDA has set a PDUFA goal date of March 16, 2027, for the review. If approved, Anaphylm would be the first oral medication for severe allergic reactions, addressing a significant unmet need.
Read more →Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Aquestive Therapeutics has appointed Rich Daly to its Board of Directors, effective October 14, 2026. Daly, a seasoned executive with over 30 years in the life sciences sector, will contribute his extensive experience in commercial launches and organizational development. His addition is seen as a strategic move as the company prepares for the potential launch of its product Anaphylm.
Read more →Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Aquestive Therapeutics has resubmitted its New Drug Application for Anaphylm™ (dibutepinephrine) sublingual film to the FDA for treating Type I allergic reactions. The resubmission follows positive results from human factors and pharmacokinetic studies. The FDA will determine the classification and review timeline of the resubmission after its initial review.
Read more →Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
Aquestive Therapeutics will participate in four investor conferences in September 2026, including the Wells Fargo Healthcare Conference and the H.C. Wainwright 27th Annual Global Investor Conference. The management team will host meetings and present key information about their innovative medicines. Webcasts of the events will be accessible for 30 days post-conference.
Read more →Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Aquestive Therapeutics completed required studies for its Anaphylm drug candidate and plans to resubmit the application to the FDA in the third quarter of 2026. The company also manufactured approximately 48 million doses in the second quarter, up from 37 million doses a year earlier. These updates accompany the firm's second quarter 2026 financial results and business progress report.
Read more →Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
Aquestive Therapeutics announced positive results from its human factors and pharmacokinetic studies for Anaphylm™ (dibutepinephrine) sublingual film. The studies support the planned resubmission of the New Drug Application (NDA) to the FDA in Q3 2026. Key improvements include faster pouch opening and reduced incorrect film placement, enhancing usability for patients at risk of anaphylaxis.
Read more →Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
Aquestive Therapeutics will report its second quarter 2026 financial results on August 11, 2026, and host a conference call for investors on August 12. The company is focused on advancing its product candidates, including Anaphylm™ and AQST-108, which target severe allergic reactions and dermatological conditions. A live webcast of the call will be available on its website.
Read more →Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
Aquestive Therapeutics will participate in the Leerink Partners Therapeutics Forum on July 14, 2026, focusing on immunology and metabolism. The management team will also host one-on-one investor meetings. The company is known for its innovative delivery technologies and is advancing treatments for severe allergic reactions and dermatological conditions.
Read more →Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Aquestive Therapeutics reported strong financial results for Q1 2026, with a revenue increase of 66% year-over-year. The company reaffirmed its plans to resubmit the Anaphylm NDA in Q3 2026 after a successful FDA Type A meeting. Additionally, AQST-108's phase 1 study showed no safety issues, supporting its potential in treating dermatological conditions. A new $150 million debt facility enhances the company's financial position for upcoming initiatives.
Read more →Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
Aquestive Therapeutics has successfully refinanced its debt with a new $150 million facility from Oaktree Capital Management. This refinancing will support the potential launch of Anaphylm, an investigational treatment for severe allergic reactions, pending FDA approval. The new agreement reduces the company's principal debt repayments significantly and provides additional capital for growth.
Read more →Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
Aquestive Therapeutics will report its first quarter 2026 financial results on May 13, 2026, and host a conference call for investors on May 14, 2026. The company aims to provide updates on its business developments and product candidates, including Anaphylm and AQST-108. A live webcast will be available for interested parties.
Read more →Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Aquestive Therapeutics has completed a Type A meeting with the FDA regarding the resubmission of its NDA for Anaphylm, a sublingual film for treating Type 1 allergic reactions. The company received valuable feedback on pharmacokinetic and human factor study designs, which will aid in their upcoming studies. The NDA resubmission is planned for Q3 2026, with further regulatory submissions also progressing in Canada and the EU.
Read more →Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
Aquestive Therapeutics has appointed Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective April 2, 2026. He succeeds Lori J. Braender, who will remain as Corporate Secretary after nearly eight years in her previous roles. Zalewski's extensive experience in life sciences law is expected to support the company's mission, particularly in advancing Anaphylm, an oral epinephrine medication.
Read more →Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
Aquestive Therapeutics granted Chief Medical Officer Matthew Greenhawt an inducement award of 75,000 restricted stock units and 50,000 stock options. The Compensation Committee approved these equity awards under the company’s 2022 Equity Inducement Plan. The grants rely on the Nasdaq Listing Rule 5635(c)(4) exemption for new hires. Vesting occurs over three years based on continued employment.
Read more →Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Aquestive Therapeutics reported its financial results for Q4 and full year 2025, highlighting progress on Anaphylm, an oral epinephrine medication. The company received a Complete Response Letter from the FDA, necessitating further studies before resubmission. Despite challenges, Aquestive remains optimistic about Anaphylm's potential, bolstered by new leadership and a growing allergy market.
Read more →Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
Aquestive Therapeutics announced its participation in four investor conferences in March 2026. The company aims to showcase its advancements in innovative medicines and delivery technologies. A webcast of the presentations will be available for 30 days post-event. The company is known for its proprietary products and contract development services.
Read more →